The selective prolyl hydroxylase inhibitor IOX5 stabilizes HIF-1α and compromises development and progression of acute myeloid leukemia
Hannah Lawson(University of London), Kamil R. Kranc(Queen Mary University of London), Paolo Gallipoli(Wellcome/MRC Cambridge Stem Cell Institute), Yuka Kabayama(MRC Centre for Regenerative Medicine), Tsz Kan Fung(King's College London), Anthony Tumber(University of Oxford), Lennart Brewitz(University of Oxford), Juerg Schwaller(University Hospital of Basel), E. Salah(University of Oxford), Nadia Saffoon(University of Oxford), Vilma Dembitz(University of Zagreb), Christopher J. Schofield(University of Oxford), Louis Dubusse(Institute of Cancer Research), Lydia M. Wang(Institute of Cancer Research), Chi Wai Eric So(London Cancer), Jozef Durko(Queen Mary University of London), Aarushi Bellani(Institute of Cancer Research), Dónal O’Carroll(MRC Centre for Regenerative Medicine), James P. Holt‐Martyn(University of Oxford), Amélie V. Guitart(MRC Centre for Regenerative Medicine), Thomas P. Corner(University of Oxford), Lewis Allen(MRC Centre for Regenerative Medicine), Louie N. van de Lagemaat(Queen Mary University of London), Azzura L. De Pace(MRC Centre for Regenerative Medicine), Derek George(Institute of Cancer Research), Christine Arndt(University of Oxford), Samanpreet Atwal(University of Oxford), Matthew Bowen(University of Oxford)
Cited by 40
Related Papers
A CRISPR Dropout Screen Identifies Genetic Vulnerabilities and Therapeutic Targets in Acute Myeloid Leukemia
|Cell Reports|2016|834
Targeting the RNA m6A Reader YTHDF2 Selectively Compromises Cancer Stem Cells in Acute Myeloid Leukemia
|Cell stem cell|2019|552
The RNA m 6 A Reader YTHDF2 Is Essential for the Post-transcriptional Regulation of the Maternal Transcriptome and Oocyte Competence
|Molecular Cell|2017|404
Structure of a cephalosporin synthase
|Nature|1998|338